ScreenerHero

FDMT 4D Molecular Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · 4dmoleculartherapeutics.com
12.59USD+0.24%Mkt Cap: 695.52M $P/E: —

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap695.52M USD
Enterprise Value371.75M USD
Revenue (TTM)92.01M USD
Gross Profit-145.10M USD
Net Income (TTM)-140.11M USD
Revenue/Share1.42 USD
Last Price12.59 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.07
PEG—
EV/EBITDA-1.97
EV/Revenue4.04
P/S7.54
P/B1.70
EPS (TTM)-2.63
EPS (Forward)-4.09
52W Range
6.96057% of range16.91
52W High16.91 USD
52W Low6.960 USD
Profitability
Gross Margin-157.70%
Oper. Margin-2037.16%
EBITDA Margin-205.30%
Profit Margin-164.43%
ROE-27.71%
ROA-24.72%
Growth
Revenue Growth25106.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.08M USD
CapEx (TTM)536.00K USD
FCF Margin-98.66%
FCF Yield-13.05%
Net Debt-322.12M USD
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.04
Current Ratio8.03
Quick Ratio7.68
Book Value/Sh7.38 USD
Cash/Share6.54 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.09 USD
Upside (mean)+123.1%
Target Range18.00 USD – 37.00 USD
18.00+123.1% to mean37.00
# Analysts11
Ownership
Shares Out.55.24M
Float42.49M
Insiders2.93%
Institutions106.04%
Short Interest
Short Ratio10.9d
Short % Float24.92%
Short % Out.21.74%
Shares Short12.01M
Short (prev mo.)12.29M
Technical
SMA 5013.46 (-6.5%)
SMA 20010.45 (+20.5%)
Beta2.74
S&P 52W Chg16.45%
Avg Vol (30d)1.10M
Avg Vol (10d)1.30M
Technical Indicators
RSI (14)39.1
MACD-0.1008
MACD Signal0.2460
MACD Hist.-0.3468
BB Upper15.93 USD
BB Middle14.12 USD
BB Lower12.30 USD
BB Width25.68%
ATR (14)0.9529 USD
Vol Ratio (20d)0.59x